for the Period Ended 31 May 2020
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 May 2020
Principal activities of the company
Directors
The directors shown below have held office during the whole of the period from
1 October 2019 to 31 May 2020
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
8 months to 31 May 2020 | 2019 | |
---|---|---|
| £ | £ |
Turnover: | | |
Cost of sales: | ( | |
Gross profit(or loss): | | |
Administrative expenses: | ( | ( |
Operating profit(or loss): | | |
Profit(or loss) before tax: | | |
Tax: | ( | ( |
Profit(or loss) for the financial year: | | |
As at
Notes | 8 months to 31 May 2020 | 2019 | |
---|---|---|---|
| £ | £ | |
Current assets | |||
Cash at bank and in hand: | | | |
Total current assets: | | | |
Creditors: amounts falling due within one year: | 3 | ( | ( |
Net current assets (liabilities): | | | |
Total assets less current liabilities: | | | |
Total net assets (liabilities): | | | |
Capital and reserves | |||
Called up share capital: | | | |
Profit and loss account: | | | |
Total Shareholders' funds: | | |
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 May 2020
Basis of measurement and preparation
Turnover policy
Intangible fixed assets amortisation policy
for the Period Ended 31 May 2020
8 months to 31 May 2020 | 2019 | |
---|---|---|
Average number of employees during the period | | |
for the Period Ended 31 May 2020
8 months to 31 May 2020 | 2019 | |
---|---|---|
£ | £ | |
Taxation and social security | | |
Other creditors | | |
Total | | |
The company has met its objectives to promote high quality healthcare in the UK during the financial period ending 31 May 2020 through the following activities:Establishing a Steering Group with senior clinicians and experts from 7 NHS Hospital Trusts to develop a national registry of metastatic breast cancer treatment in the UK. Working together with the National Institute for Health Research Brain Injury Medtech Cooperative (NIHR Brain MIC) and the Clinical Director of the National Centre for Stereotactic Radiosurgery at Royal Hallamshire Hospital, Orion MedTech has led discussions to establish a prospective database of patients undergoing stereotactic radio surgical therapy (SRS) for cerebral metastases from breast cancer. Its aims are to define current practice and to explore the interaction of systemic anti-cancer therapy with SRS in terms of disease control, survival and complications. Orion MedTech has provided its expertise to the Steering Group without charge, and expects to be able to run a national pilot at no cost to participating NHS centres by June 2021.Providing 60 benchmarking and quality assurance reports to a total of 37 NHS Trusts, which can be used to identify service improvement opportunities and best practice, for the benefit of the specialist services provided by the recipient NHS Trusts. These services include cancer treatment, epilepsy surgery for children and medical implant services to treat hydrocephalus.To maintain sustainability and financial viability, Orion MedTech has worked with the Medicines and Healthcare products Regulatory Agency and manufacturers of medical implants to provide a data analysis service which allows post-market surveillance of medical devices and identification of adverse events related to implanted devices in UK patients.Orion MedTech continues to provide software solutions and support to 37 NHS Trusts, many of which are made available without charge, or at cost.
No consultation with stakeholders
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
26 May 2021
And signed on behalf of the board by:
Name: DR Alexis JOANNIDES
Status: Director